CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence

被引:53
作者
Hongo, Fumiya [1 ]
Takaha, Natsuki [1 ]
Oishi, Masakatsu [1 ]
Ueda, Takashi [1 ]
Nakamura, Terukazu [1 ]
Naitoh, Yasuyuki [1 ]
Naya, Yoshio [1 ]
Kamoi, Kazumi [1 ]
Okihara, Koji [1 ]
Matsushima, Tomoko [2 ]
Nakayama, Satoshi [2 ]
Ishihara, Hideki [2 ]
Sakai, Toshiyuki [3 ]
Miki, Tsuneharu [1 ]
机构
[1] Kyoto Prefectural Univ Med, Dept Urol, Kyoto, Japan
[2] Sysmex Corp, Cent Res Labs, Kobe, Hyogo, Japan
[3] Kyoto Prefectural Univ Med, Dept Mol Targeting Canc Prevent, Kyoto, Japan
关键词
Renal cell carcinoma; Biomarker; Cyclin-dependent kinase; CYCLIN-DEPENDENT KINASES; EARLY BREAST-CANCER; INDEPENDENT PREDICTOR; P53; EXPRESSION; PROGNOSIS; APOPTOSIS; SURVIVAL; THERAPY; SYSTEM;
D O I
10.1016/j.urolonc.2014.05.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In renal cell carcinoma (RCC), the prediction of metastasis via tumor prognostic markers remains a major problem. The objective of our study was to evaluate the efficacy of cyclin-dependent kinase (CDK)1 and CDK2 activity as a prognostic marker in human RCC. Methods: Surgical specimens were obtained from 125 patients with RCC without metastasis. Protein expression and kinase activity of CDKs were analyzed using a newly developed assay system named C2P (Sysmex, Kobe, Japan). We then examined the specific activities (SAs) of CDK1 and CDK2 and calculated CDK2SA-CDK1SA ratio in RCC. Also, risk score (RS) was examined. Results: A total of 125 cases were tested, though 34 cases were excluded because of low sample quality (25 cases) and assay failure (9 cases). In total, 91 cases were analyzed. They included 68 male and 23 female patients, ranging in age from 19 to 83 years. At a median follow-up of 36 months (1-109M), tumor with low CDK2SA-CDK1SA ratio showed significantly better 5-year recurrence-free survival than those with high CDK2SA-CDK1SA ratio (88.7% vs. 54.7%, P = 0.00141). Also, RS enabled the classification of RCCs into high-risk and low-risk groups, and patients with tumors classified as low RS showed better recurrence-free survival than patients with tumors with high RS (88.7% vs. 54.7%, P = 0.0141). Conclusion: CDK1SA of tumors and the CDK2SA are both associated with recurrence and prognosis. Impact: CDK-based risk demonstrated is strongly associated with clinical outcome. CDK-based risk should be an accurate system for predicting recurrence and survival for planning follow-up. (C) 2014 The Authors. Published by Elsevier Inc.
引用
收藏
页码:1240 / 1246
页数:7
相关论文
共 27 条
[1]   Prognostic impact of histologic Subtyping of adult renal epithelial neoplasms - An experience of 405 cases [J].
Amin, MB ;
Amin, MB ;
Tamboli, P ;
Javidan, J ;
Stricker, H ;
Venturina, MD ;
Deshpande, A ;
Menon, M .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (03) :281-291
[2]  
Bindra RS, 2002, CANCER RES, V62, P3014
[3]  
Bui MHT, 2003, CLIN CANCER RES, V9, P802
[4]   Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe [J].
Castedo, M ;
Perfettini, JL ;
Roumier, T ;
Kroemer, G .
CELL DEATH AND DIFFERENTIATION, 2002, 9 (12) :1287-1293
[5]   Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? [J].
Colozza, M ;
Azambuja, E ;
Cardoso, F ;
Sotiriou, C ;
Larsimont, D ;
Piccart, MJ .
ANNALS OF ONCOLOGY, 2005, 16 (11) :1723-1739
[6]   Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle [J].
Golsteyn, RM .
CANCER LETTERS, 2005, 217 (02) :129-138
[7]  
HOFMOCKEL G, 1995, CANCER, V76, P296, DOI 10.1002/1097-0142(19950715)76:2<296::AID-CNCR2820760221>3.0.CO
[8]  
2-L
[9]   A new cancer diagnostic system based on a CDK profiling technology [J].
Ishihara, H ;
Yoshida, T ;
Kawasaki, Y ;
Kobayashi, H ;
Yamasaki, M ;
Nakayama, S ;
Miki, E ;
Shohmi, K ;
Matsushima, T ;
Tada, S ;
Torikoshi, Y ;
Morita, M ;
Tamura, S ;
Hino, Y ;
Kamiyama, J ;
Sowa, Y ;
Tsuchihashi, Y ;
Yamagishi, H ;
Sakai, T .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2005, 1741 (03) :226-233
[10]   Cancer statistics, 2006 [J].
Jemal, A ;
Siegel, R ;
Ward, E ;
Murray, T ;
Xu, JQ ;
Smigal, C ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2006, 56 (02) :106-130